Nasal dilators with improved breathability

Information

  • Patent Grant
  • 11344444
  • Patent Number
    11,344,444
  • Date Filed
    Saturday, April 6, 2019
    5 years ago
  • Date Issued
    Tuesday, May 31, 2022
    2 years ago
Abstract
Nasal dilators with improved comfort are formed as a laminate of layers: a resilient layer including a plurality of resilient members; and an engagement layer including one or both of a base layer and a cover layer. A portion of the dilator occupied by all of the resilient members plus the gap(s) between the resilient members has a total area, and the proportion of that area that is occupied or covered by the resilient members does not exceed 57%. Preferably, the proportion is lower than about 50%, and it may be as low as 30% in some embodiments.
Description
CONTINUITY AND CLAIM OF PRIORITY

This is an original U.S. patent application.


FIELD

The invention relates to nasal dilators. More specifically, the invention relates to nasal-dilator configurations that provide improved wearing comfort.


BACKGROUND

Dilators to improve breathing by expanding a person's nasal passages have been investigated and developed for many decades. One of the earliest external nasal dilator devices is described in U.S. Pat. No. 1,292,083 to Sawyer, and a simple forerunner of contemporary external nasal dilators was described in Spanish utility model ES_289-561 in 1985.


With the development of modern materials (including nonwoven fabrics, breathable films, and sturdy, lightweight resilient plastic sheet materials), most recent dilators have adopted one of three basic forms, shown in FIGS. 3A-C. The simplest is a “hot dog” shape (FIG. 3A): a single resilient band (which may be straight or curved) is “island-placed” within the periphery of an adhesive material Slightly more complex is the “dog bone” shape (FIG. 3B), which includes enlarged end regions comprising corner tabs, or wings, to improve adherence, and so that the resilient members may extend fully from end to end. Dog-bone dilators typically have multiple parallel resilient members, and these are often constrained along their lengths, or at least at their ends, so as to be securely integrated into a truss-like configuration. Finally, “butterfly” dilators (FIG. 3c) have multiple separate spring fingers extending outward from a common center, intending to provide dilation at discrete points about the nose. Butterfly dilators may be distinguished from dog-bone dilators in part by the fact that the lateral ends of the resilient member(s) are not constrained relative to each other; their four (or more) resilient branches are relatively free to move independently.


Note that some prior-art dilators blur the boundaries between “hot dog,” “dog bone” and “butterfly.” For example, U.S. Pat. No. 5,533,499 to Johnson discloses a dilator whose overall shape is that of a dog bone, but whose resilient members terminate short of the dilator ends, so they are island-placed.


All contemporary dilators must address several common challenges: first, they must adhere securely enough to avoid peeling off inadvertently, yet not adhere so aggressively that the user's skin is damaged when they are removed intentionally. Second, they must be comfortable for long-term (often overnight) wear. And finally, they must provide a consistent, reliable spring force to stabilize the skin and tissue over the user's nasal valve, and thereby to help open the user's nasal passages for improved respiration.


One occurrence that adversely impacts user comfort is the accumulation of moisture under the dilator—the skin to which the dilator is adhered may transpire or sweat, and the combination of perspiration and adhesive may cause itching. In some embodiments, adhesive-free areas or even absorbent pads are used to reduce the area where itching may occur. Other designs use special materials with higher moisture vapor transmission rates (MVTR). However, these materials are often more expensive than traditional materials, or are harder to work with.


Alternative approaches to reducing moisture-trapping surface area in a nasal dilator may be of substantial value in this area of technology.


SUMMARY

Embodiments of the invention are dog-bone style nasal dilators whose resilient members are positioned differently from the prior art, so that the breathable surface area of the dilator within the resilient structure's boundaries is substantially increased.





BRIEF DESCRIPTION OF DRAWINGS


FIG. 1 shows a representative embodiment of the invention.



FIG. 2 highlights important differences between embodiments and prior-art dog-bone dilators.



FIGS. 3A-3C show examples of prior-art dilators of the three major categories.



FIGS. 4A-4D show alternative material stacking orders in a laminated dilator according to an embodiment.



FIG. 5 shows another embodiment of the invention.



FIG. 6 shows another embodiment of the invention.



FIG. 7 shows another embodiment of the invention.



FIGS. 8A-8C show a protocol for measuring the resilient or spring force of a nasal dilator.





DETAILED DESCRIPTION

An embodiment of the invention is a dog-bone style nasal dilator, generally similar to the device 100 depicted in FIG. 1. Various regions of the dilator are identified in this figure, and the same terms will be used to refer to corresponding regions in both inventive and prior-art dilators.


Dilator 100 is an oblong structure which may be divided into three regions along its length: lateral end regions 132, 134 are interconnected by a narrower “waist” region 136. Similarly, across its width, the dilator may be divided into two outer portions 135 flanking a central band 137. The central band 137 includes two resilient members 122a, 122b, which extend fully from end to end of the dilator. (End-to-end resilient members allow the dilator to be manufactured more accurately and efficiently, compared to island-placed resilient members.) In use, the narrow waist region 136 is placed across the bridge of the nose, and the lateral end regions 132, 134 are pressed down and adhered against the sides of the nose and the cheeks. The resilient members are thus flexed over the bridge of the nose, and in attempting to spring back to their unflexed configuration, they lift and stabilize the skin to which they are adhered, thus opening and dilating the user's nasal passages. The outer portions 135 include corner tabs (sometimes called “tab extensions” or “wings”) that aid in maintaining the lateral end regions 132 and 134 secured to the skin of the nose. The distinguishing characteristics of an embodiment lie mostly within the central band 137, which may be viewed as a “resilient structure bounding box” 199, outlined in heavy dashed lines.



FIG. 2 compares prior-art dogbone-style two- and three-band nasal dilators with nearly identically-sized two-band dilators according to embodiments of the invention. In this Figure, the resilient members are shown as solid black bars to highlight the substantial portion of the resilient structure bounding box 199 covered by prior-art resilient members, as compared to the significantly reduced proportion covered by the resilient members in embodiments of the invention. In the prior-art dilators, the resilient members are wider than those of the embodiment, and they are also positioned much closer together (compare 210, 220 with 230, 240). The result is that the ratio of the total area of the resilient structure bounding box 199 to the area of the bounding box covered by resilient-member material is much higher in the prior art. Prior-art structures may be as much as 90% covered, whereas an embodiment is 54% or less.


The difference in surface area coverage is important because the material used for all nasal dilator resilient members is typically a nonpermeable or low-permeability plastic such as polyethyl tetraphthalate (“PET” or biaxially-oriented polyethyl tetraphthalate, “boPET”). The other portions of the resilient member bounding box may be covered by a permeable material such as a woven or nonwoven fabric or a breathable plastic film (or, in some embodiments described below, by nothing at all—i.e., by an opening that exposes the skin directly to the atmosphere). By reducing the amount of skin covered by the resilient-member material, an embodiment improves skin breathability and reduces moisture vapor accumulation, and thus improves device comfort.



FIGS. 4A-4D show several different stacking orders for the materials that are laminated into a dilator according to an embodiment. Embodiments include a layer containing the resilient members (a “resilient layer”), and: 1) a cover layer over the resilient members; 2) a base layer under the resilient members; or 3) both a cover layer and a base layer. The cover and/or base layers define the outer peripheral boundary of the dilator, and are referred to generally as the “engagement layer.” Those layers may be the same shape (i.e., the shape of the dilator outline), as shown in FIG. 4A, 414 and 418 are the same shape; or a layer may be the same shape as the resilient members (FIGS. 4c, 414a and 414b are the same shape as 422a and 422b, respectively); or the base layer may approximate the resilient-structure bounding box (FIG. 4D, base layer 414 covers just the bounding box 199); or the cover layer may be omitted entirely (FIG. 4B only includes base layer 414, which defines the dilator periphery). The various layer shapes and stacking configurations have ramifications in material use and ease of manufacture, as well as a modest effect on the performance of the dilator, but the exact choice of layers, layer shapes and stacking configuration are within the sound engineering judgment of one of ordinary skill, who can construct an embodiment by ensuring that the proportion of the resilient structure bounding box covered by resilient member material is less than a predetermined critical value.



FIG. 5 shows another embodiment of the invention 500, where a central opening 540 has been made through the base and/or cover layers (through the engagement layer), between the resilient members, and not extending all the way to the lateral ends of the dilator, so that the resilient members are still constrained, effectively connected to each other at their lateral ends via the engagement layer (550, 560). Opening 540 has a higher moisture-vapor transmission rate (“MVTR”) than even the permeable base and/or cover layer, so this dilator may be even more comfortable than a basic embodiment such as that shown in FIG. 1.



FIG. 6 shows another embodiment of the invention 600. Here, the resilient member bands are connected by a bridge in the center of the dilator (623), so they form an “H” shape, rather than two separate, parallel bands. Two openings 642, 644 expose skin on the sides of the user's nose and permit moisture to evaporate easily from the skin. This embodiment is different from the “butterfly” dilators because the ends of the resilient members—the tops and bottoms of the H shape—are still constrained: they are connected together by the base and/or cover layer (650, 660), whereas a butterfly dilator has resilient-member ends that can move independently.



FIG. 7 shows another embodiment of the invention 700. This embodiment is similar to FIG. 1, 100 and FIG. 5, 500, but instead of a single large opening 540, the engagement layer between the resilient members and within the resilient structure bounding box is pierced by a plurality of openings 740. Thus, the high-MVTR area that is all consolidated into a single opening 540 in the embodiment of FIG. 5, is spread out somewhat in the embodiment of FIG. 7.


The principal distinguishing characteristic of an embodiment is the proportion of the resilient-member surface area that is covered by low-permeability or impermeable resilient members, compared to the total surface area of bounding box 199/central band 137. An embodiment reduces that proportion (with a corresponding increase in the higher-permeability area of non-resilient-member engagement layer surface area), by making the resilient members slightly narrower, and by separating the resilient members by a greater distance, while maintaining substantially the same central band width and spring force resiliency as the prior art. Some embodiments increase the effective MVTR of the bounding box area by piercing or removing some of the engagement layer within that area.


Note that the nasal dilator embodiments depicted in the foregoing figures are proportioned substantially accurately, although some material thicknesses are slightly exaggerated in some views for clarity. In particular, plan-view widths, lengths, and therefore surface areas, are proportioned so that they can be directly compared by visual inspection. Numerically, an embodiment is distinguished by a resilient structure bounding box where no more than 57.5% of the total area is occupied by low-permeability or impermeable resilient members. In other words, considering the length and width of the resilient members and the gap(s) separating them, the area covered by the resilient members is 57.5% or less. The thickness of the resilient members can be adjusted to increase resiliency as necessary to attain the target resilient or spring force, measured as detailed below, of between about 15 grams and about 45 grams.


In a preferred embodiment, the area of the resilient structure bounding box covered by low-permeability or impermeable resilient members is about 47%—less than half. An embodiment may comprise even narrower (though thicker) resilient members. The practical lower limit is about 40-43%—beyond that limit, the resilient members become unreasonably thick, complicating manufacturing procedures.



FIGS. 8A through 8C illustrate a protocol for measuring and comparing spring force resiliency between nasal dilators of the present invention and the prior art. As seen in FIG. 8A, a first end of the nasal dilator is forced toward its opposite end in a “U” shape, with one end placed flat against the surface of a scale. Only the very ends of the resilient members (820, 830) are forced to the parallel position between the scale surface and the pressing force (FIG. 8B, distance 810), so that the resiliency of almost the full length of the resilient structure, 840, can be measured. This arrangement yields the most accurate and repeatable readings of maximum spring force resiliency, and ensures a fair comparison between different nasal dilator devices. (It may be apparent to one of ordinary skill that if more pressure is applied to the resilient member, FIG. 8c, distance 850, then longer portions of the resilient member structure, 860 & 870, are forced parallel. This shortens the length of the measured portion of the resilient member, shown at 880, and gives an incorrect, high reading for the spring force.) This protocol is also believed to be a reasonable proxy for maximum in situ spring force resiliency, in that human noses are not typically narrower than the degree of dilator flexure caused by this measurement method.


The applications of the present invention have been described largely by reference to specific examples. Variations from the specific examples are understood to be captured according to the following claims.

Claims
  • 1. A nasal dilator formed as a laminate comprising an engagement layer and a resilient layer, the laminate having a plan-view periphery defined by the engagement layer, wherein: the resilient layer comprises two adjacent, parallel resilient bands extending fully from end to end of the nasal dilator, each band having a length, width and thickness,a width of a gap between the two adjacent, parallel resilient bands exceeds a width of either of the two adjacent, parallel resilient bands, anda spring force exerted by the two adjacent, parallel resilient bands flexed in a U shape so that their ends are roughly parallel is between 15 and 45 grams.
  • 2. The nasal dilator of claim 1 wherein the gap between the two parallel resilient bands is constrained at at least both lateral ends of the two parallel resilient bands.
  • 3. The nasal dilator of claim 2 wherein the gap between the two parallel resilient bands is constrained along substantially all of a length of the gap.
  • 4. The nasal dilator of claim 1 wherein the resilient layer consists of the two parallel resilient bands.
  • 5. The nasal dilator of claim 1 wherein the gap is spanned by a portion of the engagement layer, and wherein the portion of the engagement layer is fully pierced by at least one opening.
  • 6. The nasal dilator of claim 5 wherein the at least one opening is two openings.
  • 7. The nasal dilator of claim 5 wherein the at least one opening is an array of openings.
  • 8. The nasal dilator of claim 1, wherein the two parallel resilient bands are integrated into the engagement layer by being constrained at both lateral ends thereof, respectively, by the engagement layer.
  • 9. A nasal dilator formed as a laminate of a plurality of layers, including a resilient layer and at least one of a base layer and a cover layer, the nasal dilator characterized in that: the resilient layer occupies a roughly rectangular resilient layer bounding box;the resilient layer comprises a first resilient member extending along one long side of the resilient layer bounding box;the resilient layer comprises a second resilient member extending along another long side of the resilient layer bounding box;the first resilient member and the second resilient member are separated by a resilient member gap; andan area of the resilient layer bounding box covered by the first resilient member and the second resilient member is less than 57.5% of a total area of the resilient layer bounding box.
  • 10. The nasal dilator of claim 9 wherein the first resilient member and the second resilient member are interconnected by a portion of the base layer or the cover layer, at least at lateral ends of the first and second resilient members.
  • 11. The nasal dilator of claim 9 wherein the resilient member gap is pierced by at least one opening.
  • 12. The nasal dilator of claim 9 wherein the resilient layer consists of the first resilient member and the second resilient member.
  • 13. The nasal dilator of claim 12 wherein the first resilient member and the second resilient member extend fully from end to end of the nasal dilator.
  • 14. The nasal dilator of claim 9, wherein the first resilient member and second resilient member are integrated into the at least one of the base layer and the cover layer by being constrained at both lateral ends thereof, respectively, by the at least one of the base layer and the cover layer.
US Referenced Citations (163)
Number Name Date Kind
5476091 Johnson Dec 1995 A
5479944 Petruson Jan 1996 A
5533499 Johnson Jul 1996 A
5533503 Doubek et al. Jul 1996 A
5546929 Muchin Aug 1996 A
5549103 Johnson Aug 1996 A
RE35408 Petruson Dec 1996 E
5611333 Johnson Mar 1997 A
5653224 Johnson Aug 1997 A
5706800 Cronk et al. Jan 1998 A
5718224 Muchin Feb 1998 A
5769089 Hand et al. Jun 1998 A
5890486 Mitra et al. Apr 1999 A
5931854 Dillon Aug 1999 A
5957126 Neeser Sep 1999 A
6006746 Karell Dec 1999 A
6029658 De Voss Feb 2000 A
6033422 Blach Mar 2000 A
6058931 Muchin May 2000 A
6065470 Van Cromvoirt et al. May 2000 A
6098616 Lundy et al. Aug 2000 A
6196228 Kreitzer et al. Mar 2001 B1
6244265 Cronk et al. Jun 2001 B1
6276360 Cronk et al. Aug 2001 B1
6318362 Johnson Nov 2001 B1
6357436 Kreitzer et al. Mar 2002 B1
6375667 Ruch Apr 2002 B1
6453901 Ierulli Sep 2002 B1
6470883 Beaudry Oct 2002 B1
6550474 Anderson et al. Apr 2003 B1
6694970 Spinelli et al. Feb 2004 B2
6769428 Cronk et al. Aug 2004 B2
6769429 Benetti Aug 2004 B1
7067710 Beaudry Jun 2006 B1
7114495 Lockwood, Jr. Oct 2006 B2
D639762 Brogden et al. Jun 2011 S
D644325 Brunner et al. Aug 2011 S
D644324 Brunner et al. Oct 2011 S
8047201 Guyuron et al. Nov 2011 B2
8062329 Ierulli Nov 2011 B2
D651710 Brogden et al. Jan 2012 S
8115049 Beaudry Feb 2012 B2
D659245 Ierulli May 2012 S
8188330 Beaudry May 2012 B2
D662203 Smith Jun 2012 S
D667543 Ierulli Sep 2012 S
D671643 Ierulli Nov 2012 S
D672461 Brogden et al. Dec 2012 S
D672872 Brunner et al. Dec 2012 S
D673270 Brunner et al. Dec 2012 S
8342173 Lockwood, Jr. Jan 2013 B2
8444670 Ierulli May 2013 B2
8584671 Ierulli Nov 2013 B2
8616198 Guyuron et al. Dec 2013 B2
8617199 Eull et al. Dec 2013 B2
8641852 Ierulli Feb 2014 B2
D707814 Ierulli Jun 2014 S
D707815 Ierulli Jun 2014 S
8834511 Holmes et al. Sep 2014 B2
8834512 Brown et al. Sep 2014 B1
8834514 Smith Sep 2014 B2
8858587 Ierulli Oct 2014 B2
D722161 Reyers Feb 2015 S
D722162 Reyers Feb 2015 S
D725772 Ierulli Mar 2015 S
D725773 Ierulli Mar 2015 S
9095422 Gray Aug 2015 B2
D738496 Peck Sep 2015 S
D739015 Martin Sep 2015 S
9119620 Peterson et al. Sep 2015 B2
D741997 Terulli Oct 2015 S
D741998 Martin Oct 2015 S
D743544 Ierulli Nov 2015 S
D743545 Ierulli Nov 2015 S
D743565 Engel et al. Nov 2015 S
D745147 Ierulli Dec 2015 S
9204988 Fischell Dec 2015 B1
D746982 Ierulli Jan 2016 S
D747478 Brunner et al. Jan 2016 S
D753294 Guyuron et al. Apr 2016 S
D755376 Ierulli May 2016 S
D758575 Ierulli Jun 2016 S
D758576 Ierulli et al. Jun 2016 S
D759240 Ierulli Jun 2016 S
D759241 Ierulli Jun 2016 S
D759242 Ierulli Jun 2016 S
9364367 Ierulli Jun 2016 B2
9364368 Ierulli Jun 2016 B2
9381332 Judd Jul 2016 B2
D764055 Ierulli et al. Aug 2016 S
D764662 Ierulli et al. Aug 2016 S
9414957 Fischell Aug 2016 B1
9427945 Gray et al. Aug 2016 B2
D779666 Ierulli et al. Feb 2017 S
D779667 Ierulli et al. Feb 2017 S
9566183 Fischell Feb 2017 B1
D788298 Guyuron May 2017 S
9642995 Fenton et al. May 2017 B2
D789531 Ierulli Jun 2017 S
D790058 Ierulli et al. Jun 2017 S
D790695 Ierulli Jun 2017 S
D791312 Peck Jul 2017 S
D791314 Ierulli Jul 2017 S
9730827 Ierulli Aug 2017 B2
9730828 Ierulli Aug 2017 B2
9775738 Andre Oct 2017 B2
9844456 Ierulli Dec 2017 B2
9901479 Holmes Feb 2018 B2
9901480 Ierulli Feb 2018 B2
9901481 Ierulli Feb 2018 B2
D812749 Ierulli Mar 2018 S
D813387 Ierulli et al. Mar 2018 S
D814029 Ierulli Mar 2018 S
10010442 Ierulli et al. Jul 2018 B2
1149781 Ierulli Dec 2018 A1
10328625 Gray et al. Jun 2019 B2
20080058858 Smith Mar 2008 A1
20080097517 Holmes et al. Apr 2008 A1
20080177253 Boehringer et al. Jul 2008 A1
20080257341 Ierulli Oct 2008 A1
20090125052 Pinna et al. May 2009 A1
20090234383 Ierulli Sep 2009 A1
20100210988 Dallison Aug 2010 A1
20100298861 Fenton Nov 2010 A1
20110000483 Matthias et al. Jan 2011 A1
20110054517 Holmes et al. Mar 2011 A1
20110166594 Eull Jul 2011 A1
20110224717 Lockwood Sep 2011 A1
20120004683 Gray Jan 2012 A1
20120022582 Guyuron Jan 2012 A1
20120067345 Shilon Mar 2012 A1
20120172923 Fenton Jul 2012 A1
20120209313 Ierulli Aug 2012 A1
20120232455 Beaudry Sep 2012 A1
20130104882 Ierulli May 2013 A1
20130118488 Ledogar May 2013 A1
20140194922 Ierulli Jul 2014 A1
20140148844 Andre Oct 2014 A1
20140296904 Andre Oct 2014 A1
20140350596 Smith Nov 2014 A1
20150005812 Holmes Jan 2015 A1
20150012035 Ierulli Jan 2015 A1
20150051636 Lockwood Feb 2015 A1
20150090398 Ierulli Apr 2015 A1
20150090399 Ierulli Apr 2015 A1
20150094757 Ierulli Apr 2015 A1
20150094758 Ierulli Apr 2015 A1
20150216709 Peck Aug 2015 A1
20150230966 Ierulli Aug 2015 A1
20150250637 Ierulli Sep 2015 A1
20150290021 Gray Oct 2015 A1
20150359654 Bentivegna et al. Dec 2015 A1
20160008161 Ierulli et al. Jan 2016 A1
20160278967 Ierulli Sep 2016 A1
20160278968 Ierulli Sep 2016 A1
20160339619 Gray et al. Nov 2016 A1
20170112653 Ierulli Apr 2017 A9
20170143531 Ierulli May 2017 A9
20170151084 Ierulli Jun 2017 A9
20180021163 Ierulli Jan 2018 A9
20180028346 Ierulli Feb 2018 A1
20180071131 Ierulli Mar 2018 A1
20190167464 Lovato Jun 2019 A1
Foreign Referenced Citations (2)
Number Date Country
355175 Jul 1998 EP
289561 Oct 1985 ES
Non-Patent Literature Citations (1)
Entry
Office Action dated Apr. 21, 2021 for U.S. Appl. No. 16/377,196.
Related Publications (1)
Number Date Country
20200315835 A1 Oct 2020 US